Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Business Wire•27/10/2026•07:00 ET
0
Key Highlights
- ➤Aptar Pharma and Stevanato Group launch joint pre-filled syringe system testing collaboration
- ➤Testing combines Stevanato glass syringes with Aptar elastomer components and needle shields
- ➤Evaluations cover 1 mL long and 2.25 mL syringe formats across selected configurations
- ➤Data examines needle-shield pull-off, plunger forces, and container closure integrity
- ➤Data packages and regulatory support aim to accelerate packaging decisions for injectable therapies
Expert Statements
Audrey Chardonnet, VP Global Market Development Injectables, Aptar Pharma
“We value our long-standing collaboration with Stevanato Group and the opportunity to bring our complementary expertise together at the assembled-system level.”
Audrey Chardonnet, VP Global Market Development Injectables, Aptar Pharma
“Through this joint work, we aim to provide pharmaceutical teams with earlier insight into component interactions and system performance to support informed development decisions.”
Riccardo Marcon, Senior Vice President, Sales & Marketing of Drug Containment Solutions, Stevanato Group
“As injectable therapies become increasingly complex, pharmaceutical companies need greater confidence in how packaging components perform together as complete systems.”
Riccardo Marcon, Senior Vice President, Sales & Marketing of Drug Containment Solutions, Stevanato Group
“By combining our expertise in prefillable containment solutions with Aptar Pharma's expertise in elastomeric components, we can provide customers with valuable system-level insights that support feasibility assessments, risk evaluation and more informed development decisions.”
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Joint system-level testing combines Stevanato Group glass syringes with Aptar Pharma elastomer components to provide key data earlier in development and help inform packaging decisions for sensitive biologics and other injectable therapies
Get started
Create a free account to read the full story.